IRIS
PEA, Federico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.971
AS - Asia 6.423
EU - Europa 4.509
SA - Sud America 915
Continente sconosciuto - Info sul continente non disponibili 714
AF - Africa 120
OC - Oceania 5
Totale 30.657
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.773
SG - Singapore 3.100
CN - Cina 1.246
UA - Ucraina 1.139
BR - Brasile 733
IT - Italia 681
HK - Hong Kong 677
DE - Germania 651
SE - Svezia 493
VN - Vietnam 486
RU - Federazione Russa 354
TR - Turchia 302
FR - Francia 282
FI - Finlandia 237
IE - Irlanda 220
GB - Regno Unito 175
IN - India 145
CA - Canada 99
BD - Bangladesh 74
AR - Argentina 56
IQ - Iraq 52
KR - Corea 47
MX - Messico 46
JP - Giappone 43
NL - Olanda 42
BE - Belgio 40
EC - Ecuador 38
ID - Indonesia 38
ES - Italia 33
CZ - Repubblica Ceca 31
SA - Arabia Saudita 31
ZA - Sudafrica 30
CO - Colombia 26
EU - Europa 21
PL - Polonia 20
VE - Venezuela 18
EG - Egitto 17
PH - Filippine 17
PK - Pakistan 17
IR - Iran 15
LT - Lituania 14
MA - Marocco 14
UZ - Uzbekistan 14
CL - Cile 13
KE - Kenya 13
CH - Svizzera 12
IL - Israele 12
JO - Giordania 11
UY - Uruguay 11
AZ - Azerbaigian 10
JM - Giamaica 10
RO - Romania 10
TH - Thailandia 10
TN - Tunisia 9
AE - Emirati Arabi Uniti 8
AL - Albania 8
AT - Austria 8
CR - Costa Rica 8
KZ - Kazakistan 8
MY - Malesia 8
PE - Perù 8
PT - Portogallo 8
RS - Serbia 8
BG - Bulgaria 7
BO - Bolivia 7
DO - Repubblica Dominicana 6
NP - Nepal 6
ET - Etiopia 5
TW - Taiwan 5
AU - Australia 4
BB - Barbados 4
HN - Honduras 4
HU - Ungheria 4
KH - Cambogia 4
KW - Kuwait 4
LB - Libano 4
LV - Lettonia 4
OM - Oman 4
SI - Slovenia 4
SK - Slovacchia (Repubblica Slovacca) 4
TG - Togo 4
TT - Trinidad e Tobago 4
CY - Cipro 3
EE - Estonia 3
GA - Gabon 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
LU - Lussemburgo 3
PA - Panama 3
PS - Palestinian Territory 3
PY - Paraguay 3
SD - Sudan 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
BF - Burkina Faso 2
BH - Bahrain 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
CM - Camerun 2
DK - Danimarca 2
Totale 29.916
Salva come PNG Salva come JPEG
Città #
Fairfield 2.204
Woodbridge 1.562
Ashburn 1.465
Singapore 1.423
Chandler 1.139
Houston 1.096
Ann Arbor 962
Wilmington 840
Seattle 832
Cambridge 716
Hong Kong 665
Jacksonville 640
Dallas 616
Beijing 580
San Jose 503
Dearborn 427
Boardman 362
Izmir 271
Princeton 238
Dublin 219
Lauterbourg 217
Udine 194
Council Bluffs 193
Des Moines 174
Los Angeles 164
Ho Chi Minh City 133
San Diego 125
Redondo Beach 105
Hanoi 100
New York 96
Buffalo 88
Santa Clara 88
Dong Ket 71
Munich 70
The Dalles 67
Orem 66
Helsinki 59
Falls Church 58
São Paulo 58
Redmond 57
Hefei 51
Norwalk 43
Ogden 41
Frankfurt am Main 40
Tokyo 40
Brussels 39
Nanjing 36
Seoul 36
Grafing 33
Milan 33
Brooklyn 32
Chicago 30
Ottawa 30
Montreal 29
Phoenix 29
Shanghai 27
Amsterdam 26
Denver 26
Moscow 25
Brasília 23
London 23
Grugliasco 22
Guangzhou 22
Nuremberg 22
Rio de Janeiro 22
Kunming 20
Mumbai 20
Rome 20
Atlanta 19
Chennai 19
Johannesburg 19
San Francisco 18
Warsaw 18
Baghdad 17
Jinan 17
Trieste 17
Belo Horizonte 16
Brno 16
Bologna 15
Curitiba 15
Da Nang 15
Manchester 15
Quito 15
San Mateo 15
Toronto 15
Biên Hòa 13
Boston 13
Dhaka 13
Düsseldorf 13
Haiphong 13
Jeddah 13
Naples 13
Wuhan 13
Mexico City 12
Piemonte 12
Riyadh 12
West Jordan 12
Hyderabad 11
Nanchang 11
Paris 11
Totale 20.249
Salva come PNG Salva come JPEG
Nome #
A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients? 753
A 1 year retrospective audit of quality indicators of clinical pharmacological advice for personalized linezolid dosing: one stone for two birds? 692
A regional approach to Antimicrobial Stewardship: the Friuli Venezia Giulia program 279
Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae? 227
Everolimus overexposure in a heart transplant patient receiving clarithromycin for the treatment of pneumonia 216
Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant 212
Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. 207
Polypharmacy in an Italian Regional Health system: a survey on drugs use in different healthcare settings 206
LONG-TERM OUTCOMES OF ORTHOTOPIC LIVER TRANSPLANTATION IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS AND COMPARISON WITH HUMAN IMMUNODEFICIENCY VIRUS-NEGATIVE CASES 204
Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures. 196
Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients 195
Pharmacokinetic drug interaction between everolimus and antifungal triazoles in a liver transplant patient 195
Educational and Organizational Interventions to Improve the Usefulness of Clinical Pharmacological Advice for Personalized Drug Dosing Based on Therapeutic Drug Monitoring. 193
Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. 189
Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with hematological malignancies 186
Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients 185
Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: A report of three cases 182
Cyclosporine A pharmacokinetics in rheumatoid arthritis patients after 6 months of methotrexate therapy 180
Multidrug resistance modulation in vivo: the effect of cyclosporin A alone or with dexverapamil on idarubicin pharmacokinetics in acute leukemia. 178
Linezolid underexposure in a hypothyroid patient on levothyroxine replacement therapy: A case report 178
Population pharmacokinetics and pharmacodynamics of levofloxacin in acutely hospitalized older patients with various degrees of renal function 178
Ceftolozane/tazobactam: place in therapy 177
- FLUCONAZOLE MONITORING IN LIVER TRANSPLANT RECIPIENTS 175
Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections 173
Risk factors associated with the onset of daptomycin non-susceptibility in Staphylococcus aureus infections in critically ill patients 170
Monitoring polypharmacy in healthcare systems through a multi-setting survey: Should we put more attention on long term care facilities? 167
Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis 166
Hyperlactacidemia Potentially Due to Linezolid Overexposure in a Liver Transplant Recipient 166
Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens 166
Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? 165
Continuous infusion may improve the efficacy of vancomycin in treatment of experimental endocarditis due to heterogeneous vancomycin-intermediate Staphylococcus aureus. 165
Actoxumab + bezlotoxumab combination: what promise for Clostridium difficile treatment? 165
A 5-year survey of antimicrobial susceptibility profiles of methicillin-resistant staphylococcus aureus (MRSA) isolated from patients with bloodstream infections in Northeast Italy 165
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers. 164
Linezolid underexposure in a patient co-treated with venlafaxine 164
Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. 164
Antibiotic therapy in hematological neutropenic patients: what is the news? 163
The effect of multifactorial, multidisciplinary educational interventions on appropriate use of teicoplanin 162
Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. 161
Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): Comparative pharmacokinetics and the role of therapeutic drug monitoring 161
Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions 161
Successful and safe long-term treatment of cerebral aspergillosis with high-dose voriconazole guided by therapeutic drug monitoring 161
Levofloxacin PK/PD: from sequential therapy model to high dosage for critical patients 160
What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice? 160
Antimicrobial treatment of bacterial infections in frail elderly patients: The difficult balance between efficacy, safety and tolerability 159
Cyclosporin nephrotoxicity in relation to its metabolism in psoriasis 158
Treatment of Candida Infections with Fluconazole in Adult Liver Transplant Recipients: Is TDM-guided Dosing Adaptation Helpful? 158
Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations 156
Population pharmacokinetics and pharmacodynamic target attainment of isavuconazole against aspergillus fumigatus and aspergillus flavus in adult patients with invasive fungal diseases: Should therapeutic drug monitoring for isavuconazole be considered as mandatory as for the other mold-active azoles? 156
Is empiric daptomycin effective in reducing mortality in Staphylococcus aureus bacteraemia? A real-life experience 155
Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis 154
Is MIC increase of meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae correlated with the increase of resistance rates against some other antibiotics with Gram-negative activity? 154
High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures 153
Biliary pharmacodynamic exposure to linezolid in two liver transplant patients. 153
Blood concentrations and clinical effect of cyclosporin in psoriasis 152
TDM coupled with Bayesian forecasting should be considered an invaluable tool for optimizing vancomycin daily exposure in unstable critically ill patients 152
Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients 151
Levofloxacin disposition over time in aqueous humor of patients undergoing cataract surgery 151
Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp 151
Effect of fluctuations of blood cyclosporine concentrations on renal function. 150
Plasma pharmacokinetics of antimicrobial agents in critically Ill patients 150
WSES consensus conference: Guidelines for first-line management of intra-abdominal infections 149
Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter? 148
Multidrug resistance modulation in vivo. The effect of cyclosporin alone or with dextro-verapamil on idarubicin pharmacokinetics in acute leukemia 148
Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia 147
Treatment of consecutive episodes of multidrug-resistant bacterial pleurisy with different aetiology in a heart transplant candidate: Proof of concept of pharmacokinetic/pharmacodynamic optimisation of antimicrobial therapy at the infection site 147
Pharmacokinetics and drug metabolism of antibiotics in the elderly 147
Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective 146
Major role of levofloxacin in the treatment of a case of Listeria monocytogenes meningitis 145
Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia 145
Pharmacokinetic-pharmacodynamic aspecte of antimicrobial prophylaxis with teisoplanin in patients undergoing major vascular surgery 144
Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy 143
Antimicrobial agents in elective surgery: Prophylaxis or "early therapy"? 143
Intra-abdominal penetration and pharmacodynamic exposure to fluconazole in three liver transplant patients with deep-seated candidiasis 143
HIV-INFECTED PATIENTS AND LIVER TRANSPLANTATION: WHO, WHEN AND WHY 142
A multidrug resistant tuberculosis case treated with continuous infusion of meropenem in outpatient care 141
A Comparative Analysis of the Urinary Excretion Profiles of Mesna and Argimesna Following Oral Administration to Healthy Volunteers 140
Treatment of pyogenic (non-tuberculous) spondylodiscitis with tailored high-dose levofloxacin plus rifampicin 140
Disposition of ceftobiprole during continuous venous-venous hemodiafiltration (CVVHDF) in a single critically ill patient 139
Urinary Pharmacokinetics and Theoretical Pharmacodynamics of Intravenous Levofloxacin in Intensive Care Unit Patients Treated with 500 mg b.i.d. for Ventilator-Associated Pneumonia 139
Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy 138
Teicoplanin therapeutic drug monitoring in critically ill patients: A retrospective study emphasizing the importance of a loading dose 137
Polytherapy and the risk of potentially inappropriate prescriptions (PIPs) among elderly and very elderly patients in three different settings (hospital, community, long-term care facilities) of the Friuli Venezia Giulia region, Italy: are the very elderly at higher risk of PIPs? 136
Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure 135
Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: A pharmacokinetics/pharmacodynamics-based approach 135
Successful treatment and FDG-PET/CT monitoring of HHV-6 encephalitis in a non-neutropenic patient: case report and literature review 134
Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients 134
Liposome-encapsulated daunorubicin for PGP-related multidrug resistance 134
The role of Clinical Pharmacology advices based on therapeutic drug monitoring in tailoring antimicrobial therapy in critical ill children . 132
Daptomycin in solid organ transplantation: Consideration of dosage adjustments in renal impairment 132
Reappraisal of Linezolid Dosing in Renal Impairment to Improve Safety 132
Gentamicin once-daily in enterococcal endocarditis 132
LEVOFLOXACIN PLASMA CONCENTRATION IN CRITICALLY ILL PATIENTS 131
The effect of pathophysiology on pharmacokinetics in the critically ill patient - Concepts appraised by the example of antimicrobial agents 131
Practical concept of pharmacokinetics/pharmacodynamics in the management of skin and soft tissue infections 131
An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units 131
Candida endocarditis and the impact of antifungal treatment on the corrected QT interval: a case report 130
Procalcitonin-guided antibiotic therapy: An expert consensus 130
Acute wound infections management: the ‘Don’ts’ from a multidisciplinary expert panel 129
Biocompatibility and biodegradation of different hyaluronan derivatives (Hyaff) implanted in rats 129
Totale 17.034
Salva come PNG Salva come JPEG
Categoria #
all - tutte 112.678
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 112.678
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.225 116 198 145 170 88 118 153 104 33 372 402 326
2022/20232.555 274 152 38 332 313 741 0 174 369 27 67 68
2023/2024668 126 53 20 10 114 79 20 57 71 40 28 50
2024/20253.674 111 318 216 126 137 198 189 253 433 281 470 942
2025/20267.701 573 860 823 575 1.105 702 1.015 266 564 626 343 249
2026/2027196 196 0 0 0 0 0 0 0 0 0 0 0
Totale 30.657